Lymphoma News

Emily Tonorezos, MD, MPH, Director of the Office of Cancer Survivorship at the National Cancer Institute (NCI), in the Division of Cancer Control & Population Sciences, shares what she and the agency are doing to raise awareness of and address issues that cancer survivors may face, as well as future directions in cancer survivorship research.

Lisocabtagene maraleucel (BREYANZI) is the fourth chimeric antigen receptor (CAR) T cell therapy approved for certain types of non-Hodgkin lymphoma (NHL).

Umbralisib (UKONIQ, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, has been approved for relapsed or refractory marginal zone lymphoma and follicular lymphoma.

Ask the Doctor: Should CLL patients receive the COVID vaccine while they are on treatment…

Peripheral T-cell lymphoma (PTCL) is an aggressive (fast-growing) form of non-Hodgkin lymphoma which has typically…

U.S. Food and Drug Administration (FDA) approved the first biomarker-driven therapy for pediatric ALCL.

Checkpoint inhibitors are a new class of drugs used by the immune system to determine…

The emergence of biomarking testing has provided new insights into the molecular and genetic underpinnings…